BioCryst presents real-world evidence showing reductions in attack rates in HAE

BioCryst Pharmaceuticals announced new real-world evidence showing that patients with hereditary angioedema, or HAE, who have normal C1-inhibitor level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO. The data were presented at the European Academy of Allergy and Clinical Immunology Congress in Valencia, Spain. Six patients with HAE-nC1-INH were included in the analysis. All had received previous long-term prophylaxis, and one remained on concurrent LTP. After six months of treatment with berotralstat, five patients showed a 75 to 100 percent reduction of their HAE attack rate, and one patient, who was on a concurrent dose of tranexamic acid, showed a 29 percent reduction in their HAE attack rate. No adverse events related to berotralstat were noted in five of the six patients. One patient experienced gastrointestinal symptoms upon initiation, which became milder after the first two weeks and did not lead to treatment discontinuation.